Trademark: 88981530
Word
CENTER FOR BREAKTHROUGH MEDICINES
Status Date
Tuesday, June 8, 2021
Registration Number
6382057
Registration Date
Tuesday, June 8, 2021
Filing Date
Thursday, December 12, 2019
Published for Opposition
Tuesday, January 12, 2021
40 Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting
42 Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research
Oct 19, 2022
Automatic Update Of Assignment Of Ownership
Jun 8, 2021
Registered-Principal Register
May 6, 2021
Notice Of Acceptance Of Statement Of Use E-Mailed
May 5, 2021
Allowed Principal Register - Sou Accepted
May 3, 2021
Statement Of Use Processing Complete
Apr 5, 2021
Use Amendment Filed
May 3, 2021
Divisional Processing Complete
Apr 5, 2021
Divisional Request Received
Apr 26, 2021
Case Assigned To Intent To Use Paralegal
Apr 5, 2021
Teas Statement Of Use Received
Apr 5, 2021
Teas Request To Divide Received
Mar 9, 2021
Noa E-Mailed - Sou Required From Applicant
Jan 12, 2021
Official Gazette Publication Confirmation E-Mailed
Jan 12, 2021
Published For Opposition
Dec 23, 2020
Notification Of Notice Of Publication E-Mailed
Dec 8, 2020
Approved For Pub - Principal Register
Dec 7, 2020
Teas/Email Correspondence Entered
Dec 7, 2020
Correspondence Received In Law Office
Dec 7, 2020
Teas Response To Office Action Received
Jun 30, 2020
Notification Of Non-Final Action E-Mailed
Jun 30, 2020
Non-Final Action E-Mailed
Jun 30, 2020
Non-Final Action Written
Jun 26, 2020
Assigned To Examiner
Jun 26, 2020
Previous Allowance Count Withdrawn
May 12, 2020
Withdrawn From Pub - Og Review Query
Apr 28, 2020
Assigned To Lie
Apr 22, 2020
Approved For Pub - Principal Register
Apr 22, 2020
Teas/Email Correspondence Entered
Apr 21, 2020
Correspondence Received In Law Office
Apr 21, 2020
Teas Response To Office Action Received
Mar 16, 2020
Notification Of Non-Final Action E-Mailed
Mar 16, 2020
Non-Final Action E-Mailed
Mar 16, 2020
Non-Final Action Written
Mar 12, 2020
Assigned To Examiner
Dec 16, 2019
New Application Office Supplied Data Entered In Tram
Dec 16, 2019
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
